News
WINT
0.025
+8.70%
0.002
Weekly Report: what happened at WINT last week (0420-0424)?
Weekly Report · 2d ago
Weekly Report: what happened at WINT last week (0413-0417)?
Weekly Report · 04/20 10:36
Weekly Report: what happened at WINT last week (0406-0410)?
Weekly Report · 04/13 10:40
Weekly Report: what happened at WINT last week (0330-0403)?
Weekly Report · 04/06 10:41
Windtree Therapeutics Delays Filing of Annual Report
TipRanks · 04/01 18:25
Weekly Report: what happened at WINT last week (0323-0327)?
Weekly Report · 03/30 10:41
Weekly Report: what happened at WINT last week (0316-0320)?
Weekly Report · 03/23 10:37
Weekly Report: what happened at WINT last week (0309-0313)?
Weekly Report · 03/16 10:36
Weekly Report: what happened at WINT last week (0302-0306)?
Weekly Report · 03/09 10:36
Weekly Report: what happened at WINT last week (0223-0227)?
Weekly Report · 03/02 10:35
Weekly Report: what happened at WINT last week (0216-0220)?
Weekly Report · 02/23 10:35
Weekly Report: what happened at WINT last week (0209-0213)?
Weekly Report · 02/16 10:35
Weekly Report: what happened at WINT last week (0202-0206)?
Weekly Report · 02/09 10:37
Weekly Report: what happened at WINT last week (0126-0130)?
Weekly Report · 02/02 10:37
Weekly Report: what happened at WINT last week (0119-0123)?
Weekly Report · 01/26 10:36
Weekly Report: what happened at WINT last week (0112-0116)?
Weekly Report · 01/19 10:44
Weekly Report: what happened at WINT last week (0105-0109)?
Weekly Report · 01/12 10:42
Windtree Therapeutics Announces Sudden Departure of President and COO
TipRanks · 01/07 22:15
Weekly Report: what happened at WINT last week (1229-0102)?
Weekly Report · 01/05 10:36
Weekly Report: what happened at WINT last week (1222-1226)?
Weekly Report · 12/29/2025 10:35
More
Webull provides a variety of real-time WINT stock news. You can receive the latest news about Windtree Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About WINT
Windtree Therapeutics, Inc. is a diversified company. The Company is engaged in the biotechnology business, advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. aPKCi inhibitor platform is a potential high-potency, specific, drug candidate with applications in oncology, particularly in hedgehog pathway-dependent cancers. The Company also has a licensing business model with partnership out-licenses in place. The Company is also focused on environmental services space.